CCR9


Also found in: Medical.
AcronymDefinition
CCR9C-C Chemokine Receptor 9 (gene)
References in periodicals archive ?
The oral presentation of Phase 2 data, titled "CCX282-B, an orally active inhibitor of chemokine receptor CCR9, shows anti-inflammatory and clinical activity in the treatment of Crohn's Disease" was provided today by Dr.
Room 207 Detailed results from ChemoCentryx's Phase 2 randomized clinical trial will be provided in an oral presentation (#1031) titled "CCX282-B, an orally active inhibitor of chemokine receptor CCR9, shows anti-inflammatory and clinical activity in the treatment of Crohn's Disease" by Satish Keshav, M.
ChemoCentryx's most advanced drug candidate, vercirnon (also known as Traficet-EN, CCX282, GSK1605786 or GSK'786), a specific CCR9 inhibitor, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development.
Results of the study showed CCR9 in 88 of 102 metastatic melanomas from the small intestine; in contrast, none of the 96 melanomas from other metastatic organ sites showed the CCR9 protein.
ChemoCentryx's most advanced drug candidate, CCX282-B (Traficet-EN, now designated GSK1605786, also known as GSK'786), a specific CCR9 inhibitor, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development.
Eastern Standard Time in a presentation entitled "Traficet-EN (CCX282), an Orally Active Inhibitor of Chemokine Receptor CCR9 for Treatment of Crohn's Disease.
Traficet-EN[R] is a first-in-class, orally active, anti-inflammatory agent that targets the chemokine receptor known as CCR9.
ChemoCentryx's lead compound, CCX282 (Traficet-EN, now designated GSK1605786, also known as GSK'786), a specific CCR9 antagonist, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development.
ChemoCentryx's lead compound, Traficet-EN(R), a specific CCR9 antagonist is currently in a multinational clinical trial (PROTECT-1) of greater than 400 patients with moderate-to-severe Crohn's disease.
The agreement encompasses Traficet-EN, a specific CCR9 antagonist currently in a multinational clinical trial (PROTECT-1) of greater than 400 patients with IBD, as well as three ongoing pre-agreed preclinical research programs involving named but undisclosed chemokine and chemoattractant receptor targets.
ChemoCentryx's lead compound, Traficet-EN (now designated GSK1605786, also known as GSK'786), a specific CCR9 antagonist, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development.
Traficet-EN is a highly potent and selective inhibitor of the CCR9 chemokine receptor, which is specifically expressed on inflammatory cells homing to the digestive tract.